Product Name :Pentadecapeptide Bpc 157 CAS NO.137525-51-0 MF :C62H98N16O22 MW:1419.53552 EINECS Number:212-729-3 Purity: 99.50% Apprarance:White Lyophilized Powder Specification:2mg/vial 10vials/box Storage:Lyophilized peptides although stable at room temperature for 3 months, should, be stored desiccated below -18° C. Upon reconstitution of the Read More

  1. Product Name :Pentadecapeptide Bpc 157
  2. CAS NO.137525-51-0
  3. MF :C62H98N16O22
  4. MW:1419.53552
  5. EINECS Number:212-729-3
  6. Purity: 99.50%
  7. Apprarance:White Lyophilized Powder
  8. Specification:2mg/vial 10vials/box
  9. Storage:Lyophilized peptides although stable at room temperature for 3 months, should, be stored
  10. desiccated below -18° C. Upon reconstitution of the peptide it should be stored at 4° C between 2-21 days and for future use below -18°

BPC 157 Description

  1. Pentadecapeptide BPC 157, composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice. Experimentally it has been demonstrated to accelerate the healing of many different wounds, including transected rat Achilles tendon.
  2. This study was designed to investigate the potential mechanism of BPC 157 to enhance healing of injured tendon. The outgrowth of tendon fibroblasts from tendon explants cultured with or without BPC 157 was examined. Results showed that BPC 157 significantly accelerated the outgrowth of tendon explants.
  3. Cell proliferation of cultured tendon fibroblasts derived from rat Achilles tendon was not directly affected by BPC 157 as evaluated by MTT assay. However, the survival of BPC 157-treated cells was significantly increased under the H(2)O(2) stress.

BPC 157 Abstract

  1. Pentadecapeptide BPC 157, composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice. Experimentally it has been demonstrated to accelerate the healing of many different wounds, including transected rat Achilles tendon.
  2. This study was designed to investigate the potential mechanism of BPC 157 to enhance healing of injured tendon. The outgrowth of tendon fibroblasts from tendon explants cultured with or without BPC 157 was examined. Results showed that BPC 157 significantly accelerated the outgrowth of tendon explants.
  3. Cell proliferation of cultured tendon fibroblasts derived from rat Achilles tendon was not directly affected by BPC 157 as evaluated by MTT assay. However, the survival of BPC 157-treated cells was significantly increased under the H2O2 stress. BPC 157 markedly increased the in vitro migration of tendon fibroblasts in a dose-dependent manner as revealed by transwell filter migration assay.
  4. BPC 157 also dose dependently accelerated the spreading of tendon fibroblasts on culture dishes. The F-actin formation as detected by FITC-phalloidin staining was induced in BPC 157-treated fibroblasts.
  5. The protein expression and activation of FAK and paxillin were determined by Western blot analysis, and the phosphorylation levels of both FAK and paxillin were dose dependently increased by BPC 157 while the total amounts of protein was unaltered.
  6. In conclusion, BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.

BPC 157 Applications

  1. Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects.
  2. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect.
  3. It also has shown to interact with the NO-saystem, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD.

BPC 157 Dosages

Experiments saw results with oral, peritoneal, and site injections. 10 micrograms per kg was the dose in rats for these results. This means oral or injection makes no difference, with a tiny bit of this healing becomes a whole lot easier

view more products

Want to know more?(feel free to contact us)

Whatsapp: +8618607141131

Email: lblmbb@msn.cn

Skype: godbullsteroid

Leave a Reply

Your email address will not be published. Required fields are marked *